Pay in 4 interest-free payments of $6.64 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
About this article Cite this article Kieliszek, M., Baejak, S., Bzducha-Wrbel, A
Cardiovascular Outcomes# EXSCEL Trial (Exenatide)# The EXSCEL trial (Holman et al., NEJM 2017) enrolled 14,752 patients with type 2 diabetes (73.1% with prior cardiovascular disease) and followed them for a median of 3.2 years: Primary MACE endpoint : HR 0.91 (95% CI 0.83-1.00), p=0.06 for superiority Met non-inferiority but narrowly missed superiority (p=0.06) All-cause mortality was reduced by 14% (HR 0.86, p=0.016) in a secondary analysis EXSCEL confirmed cardiovascular safety but did not prove cardiovascular benefit -- a critical distinction
Prescribing decisions are made solely by licensed clinicians following individual medical review, and completing an evaluation does not guarantee a prescription
In the research framing, a cycle runs for a defined block of weeks followed by a break, with the rationale that the GH axis responds better to a stimulus that is not permanently present
J Bras Nefrol 2024;46(1):99-106
Here, we showed that a short but extreme oversupply of fatty acids with the diet is able to worsen APAP administration
